» Articles » PMID: 7002181

A Controlled Comparison of Oxyfedrine, Isosorbide Dinitrate and Placebo in the Treatment of Patients Suffering Attacks of Angina Pectoris

Overview
Specialty Pharmacology
Date 1980 Sep 1
PMID 7002181
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

1 In a group of 23 patients with documented ischaemic heart disease who experienced angina pectoris, oral oxyfedrine (24 mg three times daily) was compared with isosorbide dinitrate (10 mg three times daily) and placebo in a double-blind double-crossover clinical trial. 2 Isosorbide dinitrate appeared no better than placebo, either in terms of symptomatic relief or ECG responses to exercise. Thirty eight per cent of patients complained of headaches and 28% had to cease taking the drug for this reason. 3 Oxyfedrine produced statistically significant improvements in both symptom level (P < 0.01) and ECG ST-segment responses to exercise (P < 0.01). The only side effect noted was a reversible loss of taste sensation by one patient. 4 Neither drug produced any adverse changes in any haematological or biochemical parameters. 5 Oxyfedrine is, therefore, to be preferred to isosorbide dinitrate, being both much better tolerated and more efficacious.

Citing Articles

Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Henkin R Drug Saf. 1994; 11(5):318-77.

PMID: 7873092 DOI: 10.2165/00002018-199411050-00004.


Oxyfederine and propranolol--a controlled trial in angina pectoris.

Whittington J, Raftery E Br J Clin Pharmacol. 1980; 10(5):439-42.

PMID: 7437255 PMC: 1430143. DOI: 10.1111/j.1365-2125.1980.tb01785.x.


Possible mechanisms of action of oxyfedrine as an antianginal drug.

Parratt J, MacKenzie J Br J Clin Pharmacol. 1981; 11(3):307-8.

PMID: 7213533 PMC: 1401618. DOI: 10.1111/j.1365-2125.1981.tb00540.x.


Comparison of oxyfedrine and atenolol in angina pectoris--a double-blind study.

Fananapazir L, Bray C Br J Clin Pharmacol. 1985; 20(4):405-10.

PMID: 3907677 PMC: 1400900. DOI: 10.1111/j.1365-2125.1985.tb05085.x.


Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease.

Kaski J, Araujo L, Maseri A Cardiovasc Drugs Ther. 1991; 5(6):991-6.

PMID: 1801897 DOI: 10.1007/BF00143526.

References
1.
STERNITZKE N, Kohler J, Lang E . [The effect of ildamen, a cardio-energetic coronary therapeutic agent, on cardiovascular dynamics]. Med Welt. 1966; (36):1910-5. View

2.
Epstein S, Braunwald E . Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med. 1966; 275(20):1106-12 contd. DOI: 10.1056/NEJM196611172752006. View

3.
Kukovetz W, Poch G . [Stimulation of adrenergic beta-receptors in the heart of normal and reserpinized guinea pigs by oxyfedrine]. Arzneimittelforschung. 1969; 19(9):1562-6. View

4.
Goldbarg A, MORAN J, Butterfield T, NEMICKAS R, Bermudez G . Therapy of angina pectoris with propranolol and long-acting nitrates. Circulation. 1969; 40(6):847-53. View

5.
Glancy D, Higgs L, OBrien K, Epstein S . Effects of ouabain on the left ventricular response to exercise in patients with angina pectoris. Circulation. 1971; 43(1):45-57. DOI: 10.1161/01.cir.43.1.45. View